Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia

Biological Psychiatry

Volumn 44, Issue 8, 1998, Pages 667-674

  Tsai, Guochuan ^a   Van Kammen, Daniel P ^b   Chen, Shao ^a   Kelley, Mary E ^b   Grier, Arik ^a   Coyle, Joseph T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glutamate; N acetylasportyl glutamate (NAAG) CT; N methyl D aspartate (NMDA); Schizophrenia

Indexed keywords

GLUTAMIC ACID; KETAMINE; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ADULT; AMINO ACID ANALYSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLUSTER ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCHIZOPHRENIA;

ADULT; BRAIN; BRAIN CHEMISTRY; GLUTAMIC ACID; HUMANS; MALE; NEUROTRANSMITTER AGENTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNAPTIC TRANSMISSION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032532459     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00151-6     Document Type: Article

References (63)

1. Alfredsson G., Wiesel F.-A. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl). 99:1989;322-327.
2. Alfredsson G., Wiesel F.-A. Relationships between clinical effects and monoamine metabolites and amino acids in sulpride-treated schizophrenia patients. Psychopharmacology (Berl). 101:1990;324-331.
3. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. 1987;American Psychiatric Press, Washington, DC.
4. Andreasen N.C. Negative symptoms in schizophrenia Definition and reliability . Arch Gen Psychiatry. 39:1982;784-788.
5. Andreasen N.C., Olsen S.A., Dennert J.W., Smith M.R. Ventricular enlargement in schizophrenia Relationship to positive and negative symptoms . Am J Psychiatry. 139:1982;297-302.
6. Andreasen N.C., Swayze V., Flaum M., et al. Ventricular abnormalities in schizophrenia evaluated with computed tomographic scanning. Arch Gen Psychiatry. 47:1990;1008-1015.
7. Andreasen N.C., Ehrhardt J.D., Swayze V.I.I., et al. Magnetic resonance imaging of the brain in schizophrenia. Arch Gen Psychiatry. 47:1990;35-44.
8. Cannon T.D., Mednick S.A., Parnas J. Genetic and perinatal determinants of structural brain deficits in schizophrenia. Arch Gen Psychiatry. 46:1989;883-889.
9. Chawluk J.B., Alavi A., Dann R., et al. Positron emission tomography in aging and dementia Effect of cerebral atrophy . J Nucl Med. 28:1987;431-437.
10. Chua S.E., McKenna P.J. Schizophrenia - A brain disease? A critical review of structural and functional cerebral abnormality in the disorder [review]. Br J Psychiatry. 166:1995;563-582.
11. Daniel D.G., Kim E., Kostianovsky D., et al. Computed tomography measurements of brain density in schizophrenia. Biol Psychiatry. 29:1991;745-756.
12. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 12:1989;1-13.
13. Doran A.R., Boronow J., Weinberger D.R., et al. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology. 1:1987;25-31.
14. Gattaz W.F., Gattaz D., Beckman H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr. 231:1982;221-225.
15. Gattaz W.F., Gasser T., Beckman H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry. 20:1985;360-366.
16. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. A dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
17. Goff D.C., Tsai G., Manoach D.S., et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
18. Grotta J. Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke. 25:1994;255.
19. Grunze H.C., Rainnie D.G., Hasselmo M.E., et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci. 16:1996;2034-2043.
20. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia [review]. Clin Neuropharmacol. 18:1995;237-249.
21. Heresco L.U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 32:1996;731-740.
22. Herrling P.L. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist Results from animal models and first results in humans . Neuropsychopharmacology. 10:(suppl 3):1994;591S.
23. Hollister J.M., Laing P., Mednick S.A. Rhesus incompatibility as a risk factor for schizophrenia in male adults. Arch Gen Psychiatry. 53:1996;19-24.
24. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
25. Kendell R.E., Juszczak E., Cole K. Obsteric complications and schizophrenia A case control study based on standardised obsteric records . Br J Psychiatry. 168:1996;556-561.
26. Kim J.S., Kornhuber C.H.H. Cerebral glutamate, neuroleptic drugs and schizophrenia Increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats . Eur Neurol. 22:1983;367-370.
27. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 20:1980;379-382.
28. Korpi E.R., Kaufmann C.A., Marnela K.-M., Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 20:1987;337-345.
29. Kotrla K.J., Weinberger D.R. Brain imaging in schizophrenia [review]. Annu Rev Med. 46:1995;113-122.
30. Kristensen J.D., Svensson B., Gordh T. The NMDA receptor antagonist CPP abolishes neurogenic 'wind up pain' after intrathecal administration in humans. Pain. 51:1992;249-253.
31. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
32. Lewis S.W. Computed tomography in schizophrenia 15 years on. Br J Psychiatry. 157:(suppl 9):1990;16-24.
33. Macciardi F., Lucca A., Catalano M., et al. Amino acid patterns in schizophrenia Some new findings . Psychiatry Res. 32:1990;63-70.
34. McDonald J.W., Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev. 15:1990;41-70.
35. Olney J.W. Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol. 30:1990;41-47.
36. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
37. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1962;799-812.
38. Pearlson G.D., Garbacz D.J., Breakey W.R., Ahn H.S., DePaulo J.R. Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder. Psychiatry Res. 12:1984;1-9.
39. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 28:1982;81-85.
40. 3H]norepinephrine release from rat hippocampal slices. J Pharmacol Exp Ther. 266:1993;796-803.
41. Quirion R., Bayorh M.S., Zerbe R.L., Pert C.V. Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides. 5:1984;967-973.
42. Raz S., Raz N. Structural brain abnormalities in the major psychoses: A quantitative review of the evidence from computerised imagings . Psychol Bull. 108:1990;93-108.
43. Renshaw P.F., Yurgelum-Todd D.A., Tohen M., Gruber S., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first episode psychosis. Am J Psychiatry. 152:1995;444-446.
44. Reveley A.M., Reveley M.A., Clifford C.A., Murray R.M. Cerebral ventricular size in twins discordant for schizophrenia. Lancet. i:1982;540-541.
45. Robinson M.B., Coyle J.T. Glutamate and related acidic excitatory neurotransmitters From basic science to clinical application . FASEB J. 1:1987;446-455.
46. Seeman M.V. Current outcome in schizophrenia Women vs. men . Acta Psychiatr Scand. 73:1986;609-617.
47. Sekiguchi M., Okamoto K., Sakai Y. Low concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkingje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res. 482:1989;87-96.
48. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 45:1991;37-45.
49. Slusher B.S., Robinson M.B., Tsai G., et al. Rat brain N-acetylated-alpha-linked acidic dipeptidase activity Purification and immunological characterization . J Biol Chem. 265:1990;21297-21301.
50. Spitzer R.L., Endicott J. Schedule for Affective Disorders and Schizophrenia - Lifetime Version. 3rd ed. 1979;New York State Psychiatric Institute, Biometrics Research, New York.
51. Susser E., Neugebauer R., Hoek H.W., et al. Schizophrenia after prenatal famine. Arch Gen Psychiatry. 53:1996;25-31.
52. Synek V., Reuben J.R. The ventricular-brain ration using planimetric measurement of EMI scan. Br J Psychiatry. 49:1976;233-237.
53. Torrey E.F. A viral-anatomical explanation of schizophrenia. Schizophr Bull. 17:1991;15-18.
54. Tsai G., Coyle J.T. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 46:1995;531-540.
55. Tsai G., Slusher B.S., Sim L., Coyle J.T. Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. J Chem Neuroanat. 6:1993;277-292.
56. Tsai G., Passani L.A., Slusher B.S., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
57. Van Horn J.D., McManus I.C. Ventricular enlargement in schizophrenia A meta-analysis of studies of the ventricle:brain ratio (VBR) . Br J Psychiatry. 160:1992;687-697.
58. van Kammen D.P., Sternberg D.E. CSF study in schizophrenia. Wood J.H. Neurobiology of Cerebrospinal Fluid. vol 1:1980;81-97 Plenum, New York.
59. van Kammen D.P., Mann L.S., Sternberg D.E., et al. Dopamine-β-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. Science. 220:1983;974-977.
60. van Kammen D.P., Kelley M.E., Gilbertson M.W., Gurklis J., O'Connor D.T. CSF dopamine beta-hydroxylase in schizophrenia Associations with premorbid functioning and brain computerized tomography scan measures . Am J Psychiatry. 151:1994;372-378.
61. Weinberger D.R., Cannon S.E., Potkin S.G., Wyatt R.J. Poor premorbid adjustment and CT scan abnormalities in chronic schizophrenia. Am J Psychiatry. 137:1980;1410-1413.
62. Weinberger D.R., DeLisi L.E., Perman G.P., Targum S., Wyatt R.J. Computed tomography in schizophreniform disorder and other acute psychiatric disorders. Arch Gen Psychiatry. 39:1982;778-783.
63. Zukin S.R., Zukin R.S., Vale W. An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release. Brain Res. 415:1987;84-89.